Pelthos Therapeutics Inc. Financing Cash Flow
Pelthos Therapeutics Inc. (PTHS) reported Financing Cash Flow of $27.52 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-13
- Pelthos Therapeutics Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Pelthos Therapeutics Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $27.52M, a 10909.20% increase year-over-year.
- Pelthos Therapeutics Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $18.02M.
- Pelthos Therapeutics Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $26.69M.
- Pelthos Therapeutics Inc. net cash provided by (used in) financing activities for fiscal 2025 was $45.34M, a 630.17% increase from fiscal 2024.
- Pelthos Therapeutics Inc. net cash provided by (used in) financing activities for fiscal 2024 was $6.21M, a 507.33% increase from fiscal 2023.
- Pelthos Therapeutics Inc. net cash provided by (used in) financing activities for fiscal 2023 was $1.02M, a 36.98% decline from fiscal 2022.
- Pelthos Therapeutics Inc. net cash provided by (used in) financing activities for fiscal 2022 was $1.62M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 9 month as first filed | Net Cash Provided by (Used in) Financing Activities 12 month | Net Cash Provided by (Used in) Financing Activities 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-13 | $27.52M 10-Q · filed 2026-08-13 | $45.54M derived: sum of 3 quarters · filed 2026-08-13 | $72.23M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2026-03-31 | $27.52M 10-Q/A · filed 2026-08-13 | $45.54M derived: sum of 2 quarters · filed 2026-08-13 | $72.23M derived: sum of 3 quarters · filed 2026-08-13 | $72.61M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-12-31 | $18.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $44.71M derived: sum of 2 quarters · filed 2026-03-19 | $45.09M derived: sum of 3 quarters · filed 2026-08-13 | $45.34M 10-K · filed 2026-03-19 | ||
| 2025-09-30 | $26.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $27.07M derived: sum of 2 quarters · filed 2026-08-13 | $27.32M 10-Q · filed 2025-11-13 | $27.25M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-06-30 | $375.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-13 | $625.00K 10-Q · filed 2026-08-13 | $553.00K derived: sum of 3 quarters · filed 2026-08-13 | -$419.01K derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-03-31 | $250.00K 10-Q/A · filed 2026-08-13 | $178.00K derived: sum of 2 quarters · filed 2026-08-13 | -$794.01K derived: sum of 3 quarters · filed 2026-08-13 | $793.27K derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2024-12-31 | -$72.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$1.04M derived: sum of 2 quarters · filed 2026-03-19 | $543.27K derived: sum of 3 quarters · filed 2026-03-19 | $6.21M 10-K · filed 2026-03-19 | $6.21M 10-K · filed 2025-03-27 | |
| 2024-09-30 | -$972.01K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $615.27K derived: sum of 2 quarters · filed 2025-11-13 | $6.28M 10-Q · filed 2025-11-13 | $6.28M 10-Q · filed 2024-11-13 | $6.71M derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $1.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $7.25M 10-Q · filed 2025-08-13 | $7.68M derived: sum of 3 quarters · filed 2025-08-13 | $7.88M derived: sum of 4 quarters · filed 2025-08-13 | ||
| 2024-03-31 | $5.67M 10-Q · filed 2025-05-13 | $6.10M derived: sum of 2 quarters · filed 2025-05-13 | $6.29M derived: sum of 3 quarters · filed 2025-05-13 | $6.52M derived: sum of 4 quarters · filed 2025-05-13 | ||
| 2023-12-31 | $430.41K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $628.54K derived: sum of 2 quarters · filed 2025-03-27 | $855.45K derived: sum of 3 quarters · filed 2025-03-27 | $1.02M 10-K · filed 2025-03-27 | ||
| 2023-09-30 | $198.13K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $425.03K derived: sum of 2 quarters · filed 2024-11-13 | $591.94K 10-Q · filed 2024-11-13 | |||
| 2023-06-30 | $226.91K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $393.81K 10-Q · filed 2024-08-13 | ||||
| 2023-03-31 | $166.90K 10-Q · filed 2024-05-15 | |||||
| 2022-12-31 | $1.62M 10-K · filed 2024-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |